Journal article
Potential kidney protective effects of glucagon-like peptide-1 receptor agonists
Philippa Trevella, Elif I Ekinci, Richard J MacIsaac
Nephrology | Wiley | Published : 2024
DOI: 10.1111/nep.14336
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gained increasing attention for their potential benefits in people with type 2 diabetes (T2DM) with chronic kidney disease (CKD). This class of medication has demonstrated promising results in reducing albuminuria, preserving estimated glomerular filtration rate (eGFR), and mitigating cardiovascular (CV) risk, making them potential therapeutic options for individuals with CKD. The kidney protective effects of GLP-1RAs extend beyond glycaemic control, and are thought to be attributed to their anti-inflammatory, antioxidant, and natriuretic properties. Despite these promising findings, the use of GLP-RAs has yet to be definitively shown..
View full abstractGrants
Funding Acknowledgements
RM: Is a principal investigator and a member of the expert global panel for the FLOW trial. Has received research grants from Novo Nordisk, Servier, Medtronic, The Rebecca Cooper Medical Research Foundation, St Vincent's Research Foundation, The Juvenile Diabetes Research Foundation, Grey Innovations, The Diabetes Australia Research Trust/Program and The National Health and Medical Research Council of Australia. Also received honoraria for lectures from Eli Lilly, Novo Nordisk, Sanofi Aventis, Astra Zeneca, Merck Sharp & Dohme, Norvartis and Boehringer Ingelheim and has been or is on the advisory boards for Novo Nordisk, Boehringer Ingelheim-Eli Lilly Diabetes Alliance, Astra Zeneca and Merck Shape and Dohme. Travel support has been supplied by Novo Nordisk, Sanofi, Boehringer Ingelheim and Astra Zeneca. Has been a principal investigator for industry-sponsored clinical trials run by Novo Nordisk, Sanofi, Bayer, Johnson-Cilag and Abbive. EIE's institution receives research funding from Eli Lilly, Novo Nordisk, Amgen, Versanis, Endogenex, Novartis, Astra Zeneca and EIE is on advisory boards and gives presentations for Eli Lilly, Astra Zeneca, Boehringer and these funds are donated towards diabetes research at EIE's institution. The Australian Centre for Accelerating Diabetes Innovations (ACADI) was established through MRFF Funding from the Australian Government's Targetted Translational Research Accelerator Program Delivered by MTP Connect. Open access publishing facilitated by The University of Melbourne, as part of the Wiley - The University of Melbourne agreement via the Council of Australian University Librarians.